{"changes":[],"country":"US","description":"Kailera Therapeutics is a clinical-stage biotech advancing GLP-1, GIP, and amylin agonist drug candidates for obesity. The customer base is patients with chronic weight-related metabolic disease. Backed by Bain Capital Life Sciences and others, Kailera ran a Phase 3 program for KAI-9531 in adults with obesity.","domain":"kailera.com","employees":null,"founded":2023,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":42.376238,"lng":-71.235564,"location":"San Diego, US","name":"Kailera Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":600000000,"currency":"USD","date":"2025-10-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-23","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"kailera-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-23","status":"attributed","url":null},{"fact":"existence","publisher":"kailera.com","retrievedAt":"2026-05-23","status":"self-reported","url":"https://kailera.com"},{"fact":"description","publisher":"kailera.com","retrievedAt":"2026-05-23","status":"self-reported","url":"https://kailera.com"}],"stage":"series-b+","techStack":["Cloudflare","WordPress","Magnific Popup","Yoast SEO 27.4","reCAPTCHA","Google Analytics","Google Tag Manager","FitVids.JS 1778785549","Font Awesome","ScrollMagic 2.0.7","jQuery Migrate","jQuery Mobile"],"totalRaisedUsd":600000000,"updatedAt":"2026-05-23"}